Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

162
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
162
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

623
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
623
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

172
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
172
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

206
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
206
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

142
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
142
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

131
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
131

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Creatine Supplementation in Preclinical Models Receiving Immune Checkpoint Inhibitor Therapy: A Systematic Review.

Cureus·2026
Same author

Pulse Wave Velocity in Atrial Fibrillation: A Scoping Review of Clinical Relevance.

Cureus·2026
Same author

Gender-Based Disparities in the Evaluation and Management of Acute Coronary Syndromes.

Cureus·2026
Same author

Janus Kinase and Interleukin-6 Inhibitor-Induced Lipid Modulation and Its Association With Major Adverse Cardiovascular Events in Rheumatoid Arthritis: A Systematic Review of Clinical and Biomarker Evidence.

Cureus·2026
Same author

Biomarkers in the Early Detection of Dementia: A Systematic Review.

Cureus·2026
Same author

Effects of Metformin on Mitochondrial Health and Oxidative Stress in Age-Related Macular Degeneration: A Systematic Review.

Cureus·2026

Related Experiment Video

Updated: Nov 11, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K

Giant Cell Arteritis and Cardiac Comorbidity.

Magela Arias1, Milad Heydari-Kamjani1, Marc M Kesselman2

  • 1Osteopathic Medicine, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Davie, USA.

Cureus
|March 23, 2021
PubMed
Summary

Giant cell arteritis (GCA) patients face increased cardiovascular disease risks due to the condition and its steroid treatment. This review highlights these risks and offers management guidance for physicians.

Keywords:
cardiac comorbiditygiant cell arteritislarge-vessel vasculitis and gca

More Related Videos

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

2.8K
Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

13.9K

Related Experiment Videos

Last Updated: Nov 11, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.4K
Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

2.8K
Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

13.9K

Area of Science:

  • Rheumatology
  • Immunology
  • Cardiology

Background:

  • Giant cell arteritis (GCA) is a large vessel vasculitis involving Th1 and Th17 cells.
  • Current GCA treatment focuses on remission and preventing vision loss.
  • A gap exists in managing post-remission GCA patients, particularly regarding cardiovascular risks.

Purpose of the Study:

  • To review cardiovascular disease (CVD) risks in GCA patients.
  • To provide recommendations for managing and following up GCA patients with CVD risks.

Main Methods:

  • Literature review focusing on CVD events in GCA.
  • Analysis of GCA pathogenesis and treatment implications for CVD.

Main Results:

  • GCA patients exhibit higher rates of strokes, aortic aneurysms/dissections, myocardial infarctions, and peripheral vascular disease.
  • Prolonged high-dose glucocorticoid therapy exacerbates CVD risks.

Conclusions:

  • Physicians must proactively assess and manage CVD risks in GCA patients.
  • Integrated management strategies are crucial for GCA patients post-remission.
  • Addressing CVD risks is vital for improving long-term outcomes in GCA.